Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fry

Showing results (161-170 of 201) with videos related to

Pageof 21
Sort By:
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 3 struggle for survival among leading diversity programsA Hal Strelnick, Vera S Taylor, Beverly Williams, et al.
BMC Cancer|June 20, 2006
The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancerAnirban P Mitra, Arpit A Almal, Ben George, et al.
Nano Letters|February 13, 2013
Homogeneous array of nanowire-embedded quantum light emittersM N Makhonin, A P Foster, A B Krysa, et al.
Journal of Medicinal Chemistry|April 26, 1996
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A M Thompson, et al.
The Journal of Biological Chemistry|March 30, 2001
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6D W Fry, D C Bedford, P H Harvey, et al.
Journal of Medicinal Chemistry|January 6, 1995
Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinasesB D Palmer, G W Rewcastle, A M Thompson, et al.
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 1 case for minority faculty development todayMarc A Nivet, Vera S Taylor, Gary C Butts, et al.
Journal of Medicinal Chemistry|December 16, 1997
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|February 16, 1996
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A J Bridges, et al.
Avian Diseases|April 1, 1995
Gangliosidosis in emus (Dromaius novaehollandiae)A J Bermudez, G C Johnson, M T Vanier, et al.
Pageof 21

Showing results (161-170 of 201) with videos related to

Sort By:
Pageof 21
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 3 struggle for survival among leading diversity programsA Hal Strelnick, Vera S Taylor, Beverly Williams, et al.
BMC Cancer|June 20, 2006
The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancerAnirban P Mitra, Arpit A Almal, Ben George, et al.
Nano Letters|February 13, 2013
Homogeneous array of nanowire-embedded quantum light emittersM N Makhonin, A P Foster, A B Krysa, et al.
Journal of Medicinal Chemistry|April 26, 1996
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A M Thompson, et al.
The Journal of Biological Chemistry|March 30, 2001
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6D W Fry, D C Bedford, P H Harvey, et al.
Journal of Medicinal Chemistry|January 6, 1995
Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinasesB D Palmer, G W Rewcastle, A M Thompson, et al.
The Mount Sinai Journal of Medicine, New York|November 21, 2008
Diversity in academic medicine no. 1 case for minority faculty development todayMarc A Nivet, Vera S Taylor, Gary C Butts, et al.
Journal of Medicinal Chemistry|December 16, 1997
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorA M Thompson, D K Murray, W L Elliott, et al.
Journal of Medicinal Chemistry|February 16, 1996
Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptorG W Rewcastle, B D Palmer, A J Bridges, et al.
Avian Diseases|April 1, 1995
Gangliosidosis in emus (Dromaius novaehollandiae)A J Bermudez, G C Johnson, M T Vanier, et al.
Pageof 21